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This study was undertaken to determine if crosstalk among the transient receptor
potential (TRP) melastatin 8 (TRPM8), TRP vanilloid 1 (TRPV1), and vascular endothelial
growth factor (VEGF) receptor triad modulates VEGF-induced Ca2+ signaling in human
corneal keratocytes. Using RT-PCR, qPCR and immunohistochemistry, we determined
TRPV1 and TRPM8 gene and protein coexpression in a human corneal keratocyte cell
line (HCK) and human corneal cross sections. Fluorescence Ca2+ imaging using both a
photomultiplier and a single cell digital imaging system as well as planar patch-clamping
measured relative intracellular Ca2+ levels and underlying whole-cell currents. The TRPV1
agonist capsaicin increased both intracellular Ca2+ levels and whole-cell currents, while
the antagonist capsazepine (CPZ) inhibited them. VEGF-induced Ca2+ transients and
rises in whole-cell currents were suppressed by CPZ, whereas a selective TRPM8
antagonist, AMTB, increased VEGF signaling. In contrast, an endogenous thyroid
hormone-derived metabolite 3-Iodothyronamine (3-T1AM) suppressed increases in the
VEGF-induced current. The TRPM8 agonist menthol increased the currents, while
AMTB suppressed this response. The VEGF-induced increases in Ca2+ influx and their
underlying ionic currents stem from crosstalk between VEGFR and TRPV1, which can
be impeded by 3-T1AM-induced TRPM8 activation. Such suppression in turn blocks
VEGF-induced TRPV1 activation. Therefore, crosstalk between TRPM8 and TRPV1
inhibits VEGFR-induced activation of TRPV1.
Keywords: human corneal keratocytes, 3-iodothyronamine, vascular endothelial growth factor, transient receptor
potential channel vanilloid 1, transient receptor potential channel melastatin 8, intracellular Ca2+, planar patch-
clamp technique, thyronamine
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INTRODUCTION
Numerous different transient receptor potential (TRP)
nonselective ionic channel subtypes are functionally expressed
on nearly every tissue in the human body. They act as polymodal
sensors of environmental stresses and induce both adaptive and
maladaptive responses under different conditions (1–3). In this
regard, TRP channels play an essential role in inflammation,
neovascularization, fibrosis, and pain perception (4–7). The
28 mammalian TRP channel subtypes are subdivided into
six main subfamilies based on differences in their amino acid
sequence homology (8). They display greater diversity in
activation mechanisms and selectivity than any other group of
ion channels. TRP vanilloid type 1 (TRPV1; capsaicin receptor)
belongs to the vanilloid subfamily and is an archetype for other
TRP ion channels that transduce a host of environmental stresses
to elicit both adaptive and maladaptive responses (9).
TRPV1 is expressed in different ocular tissues including
the corneal epithelium and endothelium (10–12), as well
as stromal fibroblasts (13) and conjunctival epithelial cells
(HCjEC) (14). Its activation in the cornea has cell type
specific effects that can either promote restoration or impair
recovery of corneal function subsequent to injury. Due to
its central role in corneal wound healing, such functional
diversity indicates the need to expand the current understanding
of mechanisms involved in modulating TRPV1 activation
(14–16). Subsequent to corneal epithelial delimited injury,
TRPV1 activation contributes to mediating the increases in cell
proliferation and migration induced by epidermal growth factor
(EGF) (17, 18). On the other hand, exposure to hypertonic
stress induces increases in pro-inflammatory cytokine expression
through TRPV1 activation in human corneal epithelial cells
(HCEC) (19). If such an effect is self-limiting, it can be
of adaptive value in protecting the cornea from pathogenic
infiltration. However, if the response does not resolve itself
such an effect can be maladaptive resulting in inflammatory
Abbreviations: 3-T1AM, 3-Iodothyronamine [endogenous thyroid
hormone (TH)-derived metabolite (20)]; AMTB, N-(3-Aminopropyl)-2-[(3-
methylphenyl)methoxy]-N-(2-thienylmethyl)benzamide hydrochloride [TRPM8
blocker (21)]; BCTC, N-(4- tertiarybutyl-phenyl)-4-(3-chloropyridin-2-yl)
tetrahydropyrazine-1(2H)-carboxamide [TRPM8/TRPV1 inhibitor (22, 23)];
BPE, Bovine pituitary extract; BSA, Bovine serum albumin; CAP, Capsaicin
[TRPV1 agonist (24)]; CD90, Cluster of Differentiation 90 (25, 26); CNV, Corneal
neovascularization; CPZ, Capsazepine [TRPV1 antagonist (24)]; DED, Dry eye
disease; DMEM, Dulbecco’s modified eagle’s medium; EGF, Epidermal growth
factor; FBS, Fetal bovine serum; HCCS, Human corneal cross sections; HCEC,
Human corneal epithelial cells (27); HCEC-12, Human corneal endothelial cells
(28); HCjEC, Human conjunctival epithelial cells (29); HCK, Human corneal
keratocytes (30); hTCEpi, Telomerase-immortalized human corneal epithelial cells
(31); KGM R© Keratinocyte BasalMedium; KTN, Keratocan [major keratan sulfate
(KS) proteoglycans in corneal stroma. (32, 33); LNCaP, Lymph Node Carcinoma
of the Prostate [human prostate adenocarcinoma cells (34)]; LUM, Lumican
[major keratan sulfate (KS) proteoglycans in corneal stroma (32, 33)]; MSC,
Mesenchymal stem cells; pHCF, Primary human corneal fibroblast cells; TBS, Tris-
buffered saline; TGF β-1, Transforming growth factor β-1; TH, Thyroid hormone;
TRPA, Transient receptor potential ankyrin; TRPC, Transient receptor potential
canonical; TRPM, Transient receptor potential melastatin; TRPs, Transient
receptor potential channels; TRPV, Transient receptor potential vanilloid; VEGFR,
Vascular endothelial growth factor receptor; α-SMA, Alpha-smooth muscle actin
(35, 36).
fibrosis and opacification (37). Similarly, stromal cell TRPV1
upregulation and activation by a severe stromal injury leads to
inflammatory fibrosis as a result of crosstalk with transforming
growth factor β-1 (TGF β-1) (38). In addition to inflammatory
fibrosis, stromal injury can lead to neovascularization arising
from increases in vascular endothelial growth factor (VEGF) gene
and protein expression (39). Even though activation of Ca2+
signaling contributes to this response to VEGF, it is unclear if
neovascularization is affected by crosstalk between VEGFR and
TRPV1.
Functional TRP melastatin type 8 (TRPM8) expression
has been characterized on corneal nerves and endothelial
cells (11, 40, 41) as well as corneal epithelial cells (42) and
conjunctival epithelial cells (14, 43). Both TRPV1 and TRPM8
are thermosensitive channels whose activity is modulated by
temperature changes encountered in daily living. TRPM8 can
be activated by moderate cooling from ∼25–28◦C, as well as by
menthol and icilin (44, 45), whereas TRPV1 increases its activity
starting at 43◦C (46).
3-Iodothyronamine (3-T1AM) is a thyroid hormone
metabolite and was detected in rodent tissues (47) and in human
serum (48). This endogenous amine stimulates TRPM8 activity,
which in turn suppresses TRPV1 activity in thyroid cells as well as
conjunctival epithelial and corneal epithelial and endothelial cells
(49, 50). Administering high doses of 3-T1AM in vivo induces
profound hypothermia within minutes in mice and hamsters
(20), whereas lower doses do not evoke hypothermia but instead
other reactions (51). Recent studies clarified some mechanisms
and propose anapyrexia and vasodilation instead of hypothermia
(52). Interestingly, TRPM8 activation by this agonist inhibited
rises in TRPV1 activity induced by capsaicin in HCEC and
HCjEC (42, 43).
Even though the cognate VEGF receptor (VEGFR) and
TRPV1 are coexpressed on corneal fibroblasts (53), it is
unclear if the Ca2+ transients mediating VEGF-induced stromal
angiogenesis stem from VEGFR-mediated activation of TRPV1
(13, 54, 55). A clear indication that neovascularization and
the increased expression of VEGF following corneal chemical
injury may depend on TRPV1 expression, is that those tissue
responses were markedly attenuated in TRPV1 knockout mice
(53). Besides neovascularization, VEGF upregulation contributes
to increased endothelial cell proliferation and migration in a
bovine wound healing model (56, 57). Furthermore, it is also
unknown if TRPM8 activation alters VEGF-induced TRPV1
activation.
In this study, we document that TRPM8 activation suppresses
TRPV1 responsiveness toward VEGFR activation. Such
disruption of VEGFR-induced TRPV1 activation suggests that
TRPM8 is potentially a viable target for the suppression of
TRPV1-induced inflammatory fibrosis and neovascularization,
which may also be of clinical relevance.
MATERIALS AND METHODS
Medium and Reagents
The Keratinocyte Basal Medium KBM R© provided by Lonza
(Köln, Germany) is referred to as the Keratinocyte Growth
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Medium KGM R©. VEGF-165 human recombinant protein
was purchased from ThermoFisher Scientific (Rockford,
IL, USA). Icilin was obtained from the Cayman Chemical
Company (Ann Arbor, Michigan, USA). BCTC and AMTB were
purchased from TOCRIS Bioscience (Bristol, UK). Accutase
was purchased from PAA Laboratories (Pasching, Austria). All
other reagents were purchased from Sigma-Aldrich (Darmstadt,
Germany).
Corneas
Human corneas were obtained from cadavers (two males, three
females, average age 75 ± 5 years). Donors provided written
consent to the Department of Anatomy, Friedrich Alexander
University Erlangen-Nürnberg (FAU), Germany. They were free
of recent ocular surface trauma, eye infections or diseases. All
corneas were dissected within 4 h and up to 24 h post-mortem.
Primary human cornea fibroblast cells (pHCF) were obtained
from corneal peripheral remnants of transplants donated to
German eye banks. Donors signed a patient consent form and
the study complied with the underlying legal requirements
and with the Helsinki Declaration. Epithelium was removed
mechanically under a stereo microscope. Corneal stroma was cut
into pieces (diameter of≈1mm), placed on 6-well petri dish and
cultivated with Dulbecco’s modified Eagle’s medium (DMEM)
HAMS F-12 (Biochrome AG, Berlin, Germany) containing 10%
fetal bovine serum (FBS, Thermo Fisher Scientific, Waltham,
USA). The medium was replaced at least every second day
and primary cell culture (passage 0) was split with trypsin at a
density of 80%. Cells were cultivated at 37◦C in a humidified
5% CO2 incubator. For the present analysis, 8 different
remnants of corneal transplantation from passage 1 to 5 were
used.
Cell Culture of HCK
SV40-immortalized human corneal keratocytes (HCK) were
kindly provided by Michaela Zorn-Kruppa et al. from the
Eppendorf-Hospital in Hamburg, Germany and cultivated
according to their protocols (30, 58, 59). For the HCK
cultivation, the same protocol was used as for the aforementioned
pHCF cells. In brief, cells were grown in KGM R© containing
recombinant human epidermal growth factor (rhEGF 0.1 ng/ml),
hydrocortisone (≈0.5µg/ml), insulin (≈5µg/ml), bovine
pituitary extract (BPE) and 0.5mM calcium chloride (CaCl2) as
well as penicillin/streptomycin in a humidified 5%CO2 incubator
at 37◦C (59). For the electrophysiological measurements, cell
confluence ranged between 50 and 80%. At these different
degrees of confluence, their electrophysiological characteristics
were invariant (60).
RNA Isolation and RT-PCR
HCK, HCEC-12 and LNCaP (human prostate adenocarcinoma)
cells were seeded in T75 flasks and grown to 80% confluence.
Cells were harvested following three different passages. Total
RNA was extracted using TRIzol R© Reagent RT (Ambion,
Austin, TX) according to manufacturer’s instructions. The
quality of extracted RNA was evaluated by NanoDrop ND-
2000 spectrophotometer (PEQLAB, Germany. DNase digestion
was performed and samples were stored at −80◦C. RNA (2
µg) was transcribed into cDNA by high capacity cDNA reverse
transcription kit (Applied Biosystems, Darmstadt, Germany).
cDNA was denatured (95◦C, 5min), first strand synthesized
(42◦C, 50min) and the reaction was terminated by heating
to 70◦C for 15min. For RT-PCR, 2 µl cDNA mixture was
used as a template in subsequent amplification reactions in
a total of 30 µl volume containing specific primers for
TRPM8 (sequences Fwd: CCTGTTCCTCTTTGCGGTGTGG
AT; Rev: TCCTCTGAGGTGTCGTTGGCTTT) generating a
621-bp product. Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was used as control (sequences Fwd: TCAACG
ACCACTTTGTCAAGCTCA; Rev: GCTGGTGGTCCAGGGG
TCTTACT) generating an anticipated 119-bp product. Each
reaction also contained red PCR Master Mix (Stratec Biomedical
AG, Birkenfeld, Germany). PCR reaction underwent the first
cycle at 95◦C for 5min, followed by 35 cycles of a repeat of
denaturation at 95◦C for 15 s, a primer-specific annealing step
at 58◦C for 30 s (TRPM8) or 60◦C for 30 s (GAPDH) and a
primer-specific elongation step at 72◦C for 45 s (GAPDH) or
at 72◦C for 7min (TRPM8), followed by a final temperature
holding at 4◦C. Eight microliters of the PCR products were
loaded on a 1.5% agarose gel and after electrophoresis
they were visualized via ethidium bromide staining under
UV light.
Quantitative RT-PCR
TRPM8 specific primers (sequences Fwd: ATGGCCGGG
ACGAGATGGACA; Rev: AGCCCCTGGTCTGCTCCCAAA)
generated 138-bp products. Aforementioned GAPDH was also
used as the reference gene in qPCR. Amplification was carried
out using theMx3000P qPCR system real-time cycler (Stratagene,
Waldbronn, Germany). For detection LightCycler R© 480 SYBR
Green I Master (Roche, Germany) was used. Amplification
was performed for 45 cycles lasting 15 s (95◦C) and 30 s
(60◦C) as previously described (15, 43). GAPDH expression
levels normalized TRPM8 gene expression levels. Melting curve
analysis was performed to confirm the specificity of the PCR
reaction. Data was processed using double delta Ct analysis. Each
of the three passages of every cell line was measured in triplicate
together with a sample without reverse transcription to exclude
genomic DNA contamination.
Immunocytochemistry
Human corneas were fixed in 4% paraformaldehyde (Roth,
Karlsruhe, Germany) for 4 h. After washing with PBS, they
were mounted in tissue-freezing medium (Leica, Wetzlar,
Germany) and 10µm thick sections were prepared. They were
incubated in Blotto blocking buffer (Thermo Scientific,Waltham,
Massachusetts, USA) at RT for 1 h and afterwards with anti-
TRPM8 (1:50, HPA024117, Sigma-Aldrich, St. Louis, Missouri,
USA) or anti-TRPV1 (1:50, ACC-030, Alomone, Jerusalem,
Israel) antibody at 4◦C overnight. After washing three times with
PBS, sections were incubated with a secondary Alexa Fluor 488-
labeled antibody (1:1000, A11070, Life Technologies, Carlsbad,
CA, USA) at RT for 1 h. The cell nuclei were counter-stained with
4’6-diamidino-2-phenylindole (DAPI D9564, Sigma-Aldrich, St.
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Louis, MO, USA) for 10min. After washing with PBS, sections
were embedded with fluorescence mounting medium (S3023,
Dako, Glostrup, Denmark) and stored at 4◦C in the dark.
Antibody specificity was confirmed as previously described (16).
All slides were examined with a Keyence Biorevo BZ9000
microscope (Keyence, Neu-Isenburg, Germany). HCK and pHCF
seeded on glass coverslips were maintained at 37◦C in a
humidified 5% CO2 incubator until they were 50–70% confluent.
Then they were fixed on ice in 4% (w/v) paraformaldehyde
for 20min and rinsed twice with PBS and permeabilized with
Triton X-100 (0.1%). For HCK TRPV1/TRPM8 and biomarker
detection, methanol fixed cells for 10min at −20◦C were used.
Non-specific antibody binding was blocked with 1% BSA. Cells
were then incubated overnight at 4◦C with a rabbit anti-TRPM8
monoclonal antibody (1:1000, Abcam, Cambridge, UK), anti-α-
SMA (1:500, EPR5368, Epitomics, Burlingame, CA, USA) (35,
36), anti-lumican (1:100, AF2846; R&D System, Minneapolis,
MN, USA) or anti-keratocan antibody (1:100, ab128304; Abcam,
Cambridge, UK) (32, 61). After washing twice with PBS, they
were then exposed to a secondary fluorescence-labeled antibody
for 1 h and mounted with DAPI for 5min. For fluorescence
visualization, a Zeiss AxioImager M2 inverted microscope (Zeiss,
Oberkochen, Germany) was used. HCK cells were cultured 3
days in 12-well cell culture plates. Vital cells were fixed for
30min using 4% formaldehyde, followed by washing three times
with Tris-buffered saline (TBS; pH 7.6, 10min each). Cells were
permeabilized with 0.1% Triton (15min) and blocked with 5%
BSA in TBS for 60min. HCK cells were incubated overnight
in a humidified chamber at 4◦C with primary CD90 antibodies
(1:200, ab181469, Abcam, Cambridge, UK) (25) diluted in
0.8% BSA in TBS. Fluorescence detection employed fluorescein
isothiocyanate conjugated secondary antibodies (1:200, F8771;
Sigma-Aldrich, St. Louis, Missouri, USA) and DAPI nuclear
counterstaining. Mounted slides were examined using light
microscopy (Axio Imager.M2; Zeiss, Jena, Germany).
CD90 Paraffin Embedded
Immunohistochemistry in Human Corneal
Stroma (pIHC)
A corneal cross section obtained from a patient with corneal
stromal fibrosis during perforating keratoplasty was used as
a positive control. Sections of this 4% formaldehyde fixed
paraffin embedded tissue were incubated at 60◦C (60min),
deparaffinized with xylol (40min) followed by isopropanol
(30min) and rehydrated through a descending alcohol series
(96, 90, 70, and 50% alcohol, 5min each) to 0.3% hydrogen
peroxide in aqua (5min) and TPB (pH 7.6, 5min). Antigen
retrieval was performed with 0.1% trypsin for 60min. Tissue
sections were permeabilized with 0.1% Triton X-100 (10min)
and blocked with 5% BSA in TBS for 60min. These tissue
sections were incubated overnight in a humidified chamber
at 4◦C with primary antibodies diluted in 0.8% BSA in
TBS against CD90 (1:30, ab181469, Abcam, Cambridge, UK).
Fluorescence detection employed fluorescein isothiocyanate
conjugated secondary antibodies (1:100, F8771; Sigma-Aldrich,
St. Louis, Missouri, USA) and DAPI nuclear counterstaining.
Mounted slides were examined using light microscopy (Axio
Imager.M2; Zeiss, Jena, Germany).
Fluorescence Calcium Imaging
HCK cells were cultivated on 15mm diameter glass cover slips
placed in a culture plate with wells until they reached a semi
confluent stage (≈60–80%). The culture conditions used to
prepare cells for immunofluorescence were the same as those
used for Ca2+ imaging. The cells were loaded with fura-2/AM
(1µM) at 37◦C for 20–40min. Loading was stopped with a
Ringer-like (control) solution containing (mM): 150 NaCl, 6
CsCl, 1 MgCl2, 10 glucose, 10 HEPES, and 1.5 CaCl2 at pH
7.4 and 317 mOsM (62). Potassium was replaced by cesium
and the coverslips were placed on an inverted microscope
stage (Olympus BW50WI, Olympus Europa Holding GmbH,
Hamburg, Germany) inside an experimental chamber containing
the same solution. This setup was connected to a digital imaging
system (TILL Photonics, Munich, Germany), outfitted for UV
excitation. Fura-2/AM fluorescence was alternately excited at
340 nm and 380 nm and monitored for different times at 500ms
intervals (63). The corresponding emission wavelength was
510 nm. The fluorescence ratio (f340nm/f380nm) was calculated
by the software. This ratio is a relative index of intracellular
Ca2+ ([Ca2+]i) levels (63). The f340nm/f380nm dynamic ratio
range was small [0.2 (42)] because single fluorescence response
signals at 340 and 380 nm were set to a fixed value to avoid
distortions of the Ca2+ responses patterns. A TRPM8 control
was provided by overexpressing TRPM8 in transfected cells and
exposing them to described agonists (42). The measuring field
was adapted to the number of cells (TILL Photonics view finding
system). Before each experiment, cells were routinely tested to
determine whether the calcium homeostasis (control baseline)
remained constant for 10min. The control measurements
are shown with open circles in the figures. All experiments
were performed at a constant room temperature (≈23◦C). If
stabilization had not occurred within the first 5min, adaptation
to room temperature was prolonged. Results are shown as mean
traces of the f340nm/f380nm ratio ± SEM (error bars in both
directions) with n-values indicating the number of experiments
per data point. For 10min, measurements were obtained from
groups of 5–10 cells at least three times. The fluorescence
ratios were normalized (control set to 1.2) and averaged
(with error bars). In addition, the fura-2-induced fluorescence
signals were alternatively acquired and evaluated using Life
Science fluorescence cell imaging software “cellSens” (Olympus,
Hamburg, Germany) in conjunction with a digital camera
(Olympus XM-10) (Figures 4G,I, 5D,F, 8F,H, 10E,I; control set
to 0.1 and 0.2, resp.). For the fluorescence excitation wavelengths
(340 and 380 nm), specific filters and a LED light source were
used (LED-Hub by Omikron, Rodgau-Dudenhoven, Germany).
Fura-2 fluorescence was alternately excited at 340 and 380 nm
and emission was detected every 5 s at 510 nm (250–3,800ms
exposure time). The relatively slow rise times of Ca2+ transients
in all experiments were a consequence of drugs being pipetted
into a stationary bath rather than a flow through system. In such a
configuration, the time delay was 1–2min between drug addition
and peak response.When using a blocker, cells were preincubated
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with the blocker for ∼30min before the measurement and
all test solutions contained the blocker. Drugs were dissolved
in dimethyl sulfoxide (DMSO) to obtain a stock solution and
diluted to provide a working concentration that did not exceed
0.1%. This DMSO concentration was nontoxic based on stable
f340nm/f380nm levels (data not shown).
Planar Patch-Clamp Recordings
Whole-cell currents were measured using a planar patch-
clamp setup (Port-a-Patch R©, Nanion, Munich, Germany) in
conjunction with an EPC 10 patch-clamp amplifier (HEKA,
Lamprecht, Germany) and controlled by PatchMaster software
(Version 2.6; HEKA, Lamprecht, Germany). A standard
intracellular solution containing (mM): 50 CsCl, 10 NaCl, 60
CsF, 20 EGTA, and 10 HEPES at pH ≈7.2 and ≈288 mOsM
was applied to the microchip (both provided by Port-a-Patch R©,
Nanion, Munich, Germany). The external solution contained
(mM): 140 NaCl, 4 KCl, 1 MgCl2, 2 CaCl2, 5 D-glucose
monohydrate, and 10 HEPES, pH ≈7.4 and osmolarity ≈298
mOsM. A single cell suspension of 5–10 µl was placed onto a
microchip having a 2.5–3 M resistance (aperture ≈1-3µm).
A negative pressure applied by a software-controlled pump
(Nanion) fixed one single cell atop the aperture. Meanmembrane
capacitance (19 ± 2 pF; n = 38) and mean access resistance (18
± 2 M; n = 38) were software calculated. Series resistances,
fast and slow capacitance transients were compensated by the
software of the patch-clamp amplifier. Series resistance did not
change markedly during an experiment. The liquid junction
potential was calculated (≈3.8mV) (64), which is in close
agreement with the measured range (≈4–7mV). Its mean value
was used to correct the measurements analyzed with the Patch-
Master software. Current recordings were all leak-subtracted
and cells with leak currents above 100 pA were excluded
from analysis. All experiments were performed at 22◦C room
temperature in an air-conditioned room to avoid confounding
responses by other thermo-sensitive TRPs. The current response
patterns were generated through application of specific voltage
step-protocols, which induced typical TRP channel whole-cell
current patterns (62). The holding potential (HP) was set
to 0mV in order to eliminate any possible contribution by
voltage-dependent Ca2+ channel activity. After confirming the
control settings, experiments were started∼10min after breaking
into a whole-cell configuration (65). Whole-cell currents were
recorded using 10mV voltage steps over a range from −60
to +130mV (10mV increments) for 400ms each. Currents
were also recorded through a voltage ramp protocol of −60 to
+130mV range and 500ms duration every 5 s. Resulting currents
were normalized with respect to cell membrane capacitance to
obtain current density (pA/pF) values displayed in current vs.
voltage plots.
FIGURE 1 | Confirmation of HCK identity. (A) The green anti-LUM antibody immunofluorescent (IF) staining is delimited in the endoplasmic reticulum (arrows). (B)
Anti-α-SMA antibody IF staining pattern. Their green staining pattern is less intense. Approximately 20–30% of the HCK cells have no IF signal (arrow heads). (C) IF
green staining with anti-KTN antibody detected in all HCKs. (D) A negative control (Ctrl) omitted primary antibody and does not provide a specific IF signal. In all
experiments, cell nuclei were counterstained with DAPI (blue) and pictures were merged. Pictures are representative of IF results from five different assays (n = 5).
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FIGURE 2 | Mesenchymal stem cell identification in HCK and pIHC. (A) Nuclear staining of HCK with DAPI (blue). (B) Anti CD90 IF antibody green staining detected in
HCK. (C) Merged B image with DAPI blue staining of cell nuclei. (D) DAPI blue staining of nuclei in HCK. (E) Omission of anti-CD90 antibody green staining pattern
validates primary antibody in HCK. (F) Similar as E but with DAPI (blue) (merged). (G) Nuclear staining of human corneal stroma (pIHC) with DAPI (blue). (H) IF
analyses of anti-CD90 antibody green staining in pIHC as a positive control. (I) Merged image shown in H panel with DAPI blue counterstaining.
Statistical Analysis
Significance was determined using Student’s t-test for paired data
(p-values: two-tailed) provided they passed a software available
normality test. If the normality test failed, non-parametric
Wilcoxon matched pairs were used. For non-paired data,
Student’s t-test for unpaired data was used, if it passed a normality
test. Alternatively, the non-parametric Mann-Whitney-U test
was performed. Welch’s correction was applied if data variance
of the two groups were not at the same level. Probabilities of
p < 0.05 [indicated by asterisks (∗) and hashtags (#)] were
considered to be significant. In addition, normally distributed
data of more than two groups were statistically analyzed using
one-way ANOVA (one-way analysis of variance). Selected pairs
of columns were tested using Bonferroni post-test. If the data
were not normally distributed, Kruskal-Wallis test was used and
selected pairs of columns were tested using Dunn’s post-test.
Significance level alpha = 0.05 (95% confidence intervals). The
number of repeats is shown in each case in brackets, near the
traces or bars. All values are means ± SEM (error bars in both
directions). All plots were generated with SigmaPlot software
version 12.5 for Windows (Systat Software, San Jose, California,
U.S.A.). Bar charts were plotted and statistical analyses were
performed using GraphPad Prism (version 5.00 for Windows)
(La Jolla, California, USA.).
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FIGURE 3 | TRPV1 protein expression in human cornea and primary human cornea fibroblast (pHCF) cells. IF analyses show TRPV1 (A,B) in human cadaver corneal
cross sections. Stromal keratocytes (arrows) and corneal epithelial cells (CEC) clearly have a distinct subcellular origin (green). Cell nuclei were counterstained with
DAPI (blue). The overlay of fluorescence with bright field picture (B) demonstrates parallel arrangement of the collagen fibrils (*) and the stromal keratocytes in between
the lamellae. Inlays show higher magnification of stromal keratocytes. Pictures are representative of IF staining patterns from five cadaver corneas (n = 5). IF analyses
reveal TRPV1 expression in pHCF at passage 1 (C,D) and passage 5 (E,F). (G,H) Anti-α-SMA antibody IF staining in primary human cornea fibroblast cells (passage
1). Arrows identify cells lacking IF staining signal. Notable, the green α-SMA IF staining pattern is partial and intense.
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FIGURE 4 | Confirmation of protein and functional TRPV1 expression in cultivated human corneal keratocytes (HCK). (A,B) Localization of TRPV1 in
SV40-immortalized human corneal keratocytes (HCK). IF analysis reveal subcellular TRPV1 expression (green) in all HCK cells. Cell nuclei were counterstained with
DAPI (blue) and pictures were merged. Pictures are representative of IF results from different cell passages. (C) Temperature increase from ≈ 23◦C to > 43◦C
increased [Ca2+]i (n = 4). The corresponding temperature time course is shown above the Ca
2+ traces. The thermal and pharmacological changes were carried out
at the time points indicated by arrows. (D) CAP (20µM) induced an irreversible increase in Ca2+ influx (n = 8) whereas non-treated control cells maintained a constant
Ca2+ baseline (n = 30). (E) Same experiment as shown in (D), but in the presence of capsazepine (CPZ). CPZ (20µM) suppressed the CAP-induced Ca2+ increase
(Continued)
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FIGURE 4 | (n = 6). (F) Summary of the experiments with CAP and heat stimulation. The asterisks (*) designate significant increases in [Ca2+]i with CAP (n = 8; p <
0.05 at the minimum; paired tested). The hashtags (#) indicate statistically significant differences in fluorescence ratios between CAP with and without CPZ (n = 6–8; p
< 0.01 at the minimum; non-paired tested). (G) CAP (10µM) induced a reversible increase in Ca2+ influx (n = 9) whereas non-treated control cells maintained a
constant Ca2+ baseline (n = 10). (H) Same experiment as shown in (G), but in the presence of capsazepine (CPZ). CPZ (10µM) suppressed the CAP-induced Ca2+
increase (n = 12). (I) Summary of the experiments with CAP and CPZ. The asterisks (*) designate significant increases in [Ca2+]i with CAP (n = 9; p < 0.05; paired
tested). The hashtag (#) denotes a statistically significant difference in fluorescence ratios between CAP with and without CPZ (n = 9–12; p < 0.05; non-paired tested).
RESULTS
Validation of HCK Identity
The expression of lumican (LUM), a biomarker of keratocytes,
was discernible along with LUM derived green fluorescence,
which was localized in the cytoplasm, and also in the endoplasmic
reticulum (ER) (66, 67) (Figure 1A). This expression pattern
is similar to results obtained with an anti-keratocan (KTN)
antibody (Figure 1C), which is a more specific keratocyte marker
than LUM. Alpha-smooth muscle actin (α-SMA) expression
patterns were different from the patterns with the LUM and
KTN biomarker. The α-SMA expression patterns are indicative
of myofibroblast coexpression (67). In this case, up to 30% of
HCK cells were immunofluorescent (IF). Another 20–30% of
these cells displayed a diffuse IF signal whereas ∼40–50% of
the HCK cells did not express α-SMA (Figure 1B). In controls,
omission of the primary antibody eliminated IF (Figure 1D).
The specificity of the LUM, KTN and α-SMA antibodies was
verified by showing absence of any IF staining in telomerase-
immortalized human corneal epithelial (hTCEpi) cells (31). LUM
specificity agrees with its failure to stain pHCF cells (data not
shown). CD90 is a biomarker of mesenchymal stem cells (MSC)
derived from keratocytes in vitro. It was also detectable in the
cultured stromal cells (HCK) (Figure 2) (68). Immunostaining
patterns were eliminated by omitting the primary antibody
(Figure 2E). The MSC marker expression panel shows that
keratocytes constitute a majority of the cell types in the HCK
cell line. They are accompanied by a subpopulation of fibroblasts
and myofibroblasts and some mesenchymal stem cells. Such a
mixture is unavoidable especially in a serum containing medium
since under this condition keratocytes spontaneously undergo
transformation acquiring a (myo)fibroblast phenotype (66, 69).
TRPV1 Protein Expression
TRPV1 was identified in corneal stromal cells of human corneal
cross sections (HCCS) as well as in primary human corneal
fibroblast (pHCF) cells at different cell passages. The anti-TRPV1
antibody exhibited a consistent cytoplasmic staining pattern in all
analyzed cell passages 1–5 (Figures 3A,F). Furthermore, α-SMA-
derived green fluorescence was localized in the cytoplasm in
about 50% of pHCF (passage 1) (Figures 3G,H). Some HCF cells
were not stainable with any of the aforementioned antibodies
(arrows), which is consistent with the presence of fibroblasts
and myofibroblasts derived from keratocytes. Figures 4A,B
demonstrate the localization of TRPV1 in SV40-immortalized
HCK cells, which were used in the following functional assays.
Functional TRPV1 Channel Expression
Raising the bath solution temperature to >43◦C (Figure 4C,
upper trace) increased the fluorescence ratio from 1.2000 ±
0.0001 to 1.2050 ± 0.0013 after 590 s in immortalized HCK
(n = 4; Figure 4C). Similarly, activation of TRPV1 by 20µM
µM capsaicin (CAP) irreversibly increased the fluorescence
ratio from 1.2000 ± 0.0002 to 1.213 ± 0.0028 after 590 s (n
= 8; p < 0.01; Figure 4D), whereas this rise was blocked
by 20µM capsazepine (CPZ) (1.201 ± 0.0007; n = 6; p
< 0.001; Figures 4E,F). To avoid desensitization and cell
death with over stimulation, experiments were repeated using
a lower concentration of CAP and CPZ (both 10µM) in
combination with an alternative fluorescence signal measuring
setup (Figures 4G,H,I). The results are comparable. However,
a recovery of the CAP-induced Ca2+ increase could be clearly
suppressed in the presence of 10µM CPZ (Figure 4H). More
specifically, activation of TRPV1 by 10µM CAP reversibly
increased the fluorescence ratio from 0.0969 ± 0.0031 to
0.2050 ± 0.0394 after 132 s (n = 9; p < 0.05; Figure 4G),
whereas this rise could be blocked by 10µM CPZ (0.1041 ±
0,0017; n = 12; p < 0.05; Figures 4H,I). The changes and the
underlying whole-cell currents were determined by measuring
the time dependent changes in currents along with evaluating
the plots of the corresponding current voltage relationships
at the indicated time points: A, B and C (Figures 5A,B). At
positive pipette potentials, CAP (10µM) activated outwardly
rectifying currents that were larger than those at negative
voltages (Figure 5B). As already observed in HCjEC, L-carnitine
(1mM) is a TRPV1 antagonist (15) and it reduced maximal
negative and maximal positive current amplitudes induced by a
voltage step from −60 to +130mV (% of control) (15) shown
in Figure 5C. In each measured cell, 10µM CAP increased
both in- and outward currents, whereas 1mM L-carnitine
suppressed them (n = 6; p < 0.05 at the minimum). In addition,
functional TRPV1 expression could be also documented with
the classical TRPV1 antagonist CPZ (10µM) (n = 5; p <
0.05; Figure 5C). In some previous studies as well as this
study, 20µM CAP was used to elicit physiological responses
in human corneal endothelial cells (11), corneal epithelial cells
(60), retinoblastoma cells (70) and in neuroendocrine tumor
cells (71). Regarding the effect of L-carnitine, fluorescence Ca2+
imaging results mirrored those obtained in the patch-clamp
experiments (Figures 5D,F). The CAP-induced Ca2+ increase
(n = 55; control n = 9) could be clearly suppressed in the
presence of 1mM L-carnitine (Figures 5E,F; n = 55; p < 0.005).
Overall, functional TRPV1 channel expression in HCK was
confirmed using different CAP and CPZ concentrations. This
was evident because the results obtained with two different
fluorescence calcium monitoring systems corresponded with
those detected with the patch-clamp technique. In summary,
functional TRPV1 expression is present in all types of stromal
cells.
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FIGURE 5 | CAP activated whole-cell currents in HCK. (A) Time course recording of the current increases induced by CAP (10µM) and decline after application of
1mM L-carnitine. (B) Original traces of CAP-induced current responses to voltage ramps. Current densities are shown before application (labeled as A), during
application of 10µM CAP (labeled as B), and after addition of 1mM L-carnitine (labeled as C). Calculated current densities obtained by normalizing currents to
(Continued)
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FIGURE 5 | membrane capacitance as function of imposed voltage were derived from the traces shown in (A). (C) Summary of the experiments with CAP, L-carnitine
and CPZ. Ten micromolar CAP induced an increase of normalized maximal in- and outward whole-cell currents (for −60mV control was set to −100%; for 130mV
control was set to +100%; n = 13). This increase could be suppressed by 1mM L-carnitine and 10µM CPZ, respectively (n = 5–6). Data passed the normality test
and were statistically analyzed using one-way ANOVA (one-way analysis of variance). Selected pairs of columns were tested using Bonferroni post-test. The asterisks
(*) designate significance differences between the columns (n = 5–13; p < 0.05 at the minimum). Significance level alpha = 0.05 (95% confidence intervals). (D) CAP
(10µM) induced an irreversible increase of intracellular Ca2+ concentration (n = 55) whereas non-treated control cells maintained a constant Ca2+ baseline (n = 9).
(E) Same experiment as shown in (D), but in the presence of L-carnitine. L-carnitine (1mM) suppressed the CAP-induced Ca2+ increase (n = 55). (F) Summary of the
experiments with CAP and L-carnitine. Data were statistically analyzed using one-way ANOVA (and Nonparametric) (one-way analysis of variance) (Kruskal-Wallis test).
Selected pairs of columns were tested using Dunns post-test. The asterisks (*) designate significance differences between the columns (n = 55; p < 0.005).
Significance level alpha = 0.05 (95% confidence intervals).
TRPM8 Gene and Protein Expression
RT-PCR and semi-quantitative real-time PCR identified TRPM8
gene expression in HCK (Figures 6A,B) based on generating
the predicted TRPM8 621-bp amplicon (Figure 6A). qPCR
confirmed its identity because the size of this product was
identical with its positive control in the LNCaP cell line (72,
73) and corneal endothelial cells (41). In addition, TRPM8
immunostaining expression was identified in both the cell
membrane and peri-nuclear regions (Figures 6C,D,E). Absence
of immunostaining caused by omission of the primary antibody
excluded nonspecific secondary antibody staining. IF analyses
also detected TRPM8 expression, on keratocytes in HCCS
(Figures 6F,G).
Functional TRPM8 Channel Expression
Menthol (200 µM−1mM) probed for functional TRPM8
expression (74). This selective TRPM8 agonist at 500µM
irreversibly increased the f340nm/f380nm ratio from 1.2000 ±
0.0004 to 1.213 ± 0.003 after 590 s in HCK (n = 20; p
= 0.001; Figure 7A), whereas the mixed TRPV1/ TRPM8
antagonist, 20µM BCTC, blocked the menthol-induced Ca2+
increase (1.186 ± 0.0084; n = 14; p < 0.001); Figure 7B) (22).
Similarly, 20µM AMTB, a selective TRPM8 antagonist (21, 75),
completely blocked this response (1.197 ± 0.0066; n = 5; p <
0.05; Figure 7C). Furthermore, TRPM8 involvement is indicated
because constant moderate cooling (≈14◦C; Figure 8A, upper
trace) increased the f340nm/f380nm ratio from 1.2000 ± 0.0001
to 1.2100 ± 0.0032 after 590 s (n = 6; Figure 8A) whereas in
non-stimulated controls, the f340nm/f380nm ratio was invariant
(n = 30; Figure 8A). Icilin, is a super-cooling agent that
has higher potency and efficacy than menthol in cellular and
behavioral studies (44, 76). Sixty-µM icilin irreversibly increased
the fluorescence ratio from 1.2010 ± 0.0003 to 1.2130 ± 0.022
after 590 s (n = 13; p < 0.001; Figure 8B), which BCTC
(20µM) (Figure 8C) and AMTB blocked (10µM; 1.1980 ±
0.0018; n = 7; p < 0.001; Fig 8D). The statistical evaluation
is shown in Figure 8E. Similar results were obtained with a
lower icilin concentration (10µM) in combination with AMTB
(Figures 8F,G,H). Even though both of the increases in Ca2+
induced by menthol and icilin were blocked by AMTB, the
difference in their increases stems from the fact that each of these
mixed TRPM8/TRPA1 agonists have different TRPM8 selectivity
(77). Although high icilin concentrations were used in human
corneal epithelial cells [e.g., 15–60µM (42)], 10µM instead of
60µM icilin was used in the aforementioned set of experiments
to avoid any confounding effects with overstimulation. As shown
in Figure 8F, a partial reversible calcium response could be
observed in comparison to the irreversible calcium response
shown in Figure 8B of the same experiment. Since icilin activates
both TRPM8 and TRPA1 (78, 79), AMTB (10µM), a highly
selective TRPM8 blocker, was used to probe for TRPM8 (21, 80).
Specifically, icilin reversibly increased the fluorescence ratio from
0.2045± 0.0019 to 0.2477± 0.0165 after 400 s (n= 16; p< 0.001;
Figure 8F), which AMTB blocked (10µM; 0.2021 ± 0.0020; n =
16; p < 0.001; Figures 8G,H). In summary, functional TRPM8
channel expression in HCK was confirmed using a lower icilin
concentration in an alternative calcium imaging setup.
Cooling Compounds Induce Increases in
TRPM8-Mediated Whole-Cell Currents
In HCK, the increases in inward currents induced by 60µM icilin
(Figures 9A,B) are mainly attributable to Ca2+ influx driven
by the favorable electrochemical gradient established by a large
chemical driving force and a negative intracellular membrane
voltage whereas the Na+ electrochemical gradient is at lower
levels since the internal solution is not Na+-free. At−60mV, the
inward currents rose from −5.4 ± 1.1 (control) to −18.4 ± 4.7
pA/pF (p < 0.001; n = 16; Figure 9E), which is attributable to
increasing the inwardly directed electrical driving force whereas
the control currents remained at lower levels (Figure 9A). BCTC
suppressed this rise to −6.0 ± 3.0 pA/pF (p < 0.05; n = 4;
Figure 9E). Similarly, menthol (100µM) increased the inward
currents from −9.9 ± 1.6 pA/pF (control) to −25.4 ± 2.9 pA/pF
(p< 0.01; n= 10; and 20µMAMTB suppressed this rise to−16.5
± 2.8 pA/pF (p < 0.05; n = 5; Figures 9C,F). This result affirms
cell membrane delimited functional TRPM8 expression.
VEGF-Induced Increases in Ca2+ Influx and
Whole-Cell Currents
To clarify if VEGFR mediates TRPV1 activation in HCK,
the effects of 10 ng/ml VEGF on Ca2+ influx and whole-cell
currents were measured with and without CPZ. This growth
factor increased the f340nm/f380nm ratio from 1.2010 ± 0.0003
to 1.2120 ± 0.0030 (590 s) (n = 12; p < 0.01, Figure 10A)
whereas cells pretreated with 10µM CPZ caused the Ca2+
transients to even fall below their baseline value (1.1930 ±
0.0070; n = 4; p < 0.01) (Figures 10B,D). To ascertain if
VEGFR interacts also with TRPM8, we determined if 20µM
AMTB inhibited a VEGF induced Ca2+ transient. Unlike
CPZ, AMTB had no effect on VEGF-induced increases in the
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FIGURE 6 | TRPM8 gene and protein expression in HCK. (A) Conventional RT-PCR indicates mRNA signal of TRPM8 amplicon (621-bp) in human corneal
keratocytes (HCK), human corneal endothelial cells (HCEC-12) and human prostate cancer cells (LNCaP) as a positive control. (B) Quantitative real-time RT-PCR
analysis. The data were normalized to LNCaP with the positive mRNA signal. GAPDH was used as a housekeeping gene for normalization. Data are the mean ± SEM
of 3 independent triplicate experiments. (C–E) Immunocytochemistry documents subcellular TRPM8 localization. (C) Nuclear staining with DAPI (blue). (D) TRPM8
positive cells (red). (E) merged. (F,G) IF analyses identify TRPM8 expression in human cadaver corneal cross sections. Stromal keratocytes (arrows) and corneal
epithelial cells (CEC) clearly show a subcellular IF signal (green). Cell nuclei were counterstained with DAPI (blue). The overlay of fluorescence with bright field picture
demonstrate parallel arrangement of the collagen fibrils (*) and stromal keratocytes interspersed between the lamellae. Inlays show higher magnification of stromal
keratocytes. Pictures are representative of IF results obtained from five cadaver corneas (n = 5).
f340nm/f380nm ratio indicating that the increases in currents
induced by VEGF are only due to crosstalk between VEGFR and
TRPV1 (Figures 10C,D). Long-term calcium imaging recordings
(20min) revealed a recovery effect of VEGF (n = 12; p <
0.005) (Figures 10 E,F). The CPZ-induced suppression of the
VEGF effect was confirmed using the aforementioned alternative
fluorescence calcium imaging setup (n = 8–10; p < 0.005;
unpaired tested) (Figures 10G,I). Specifically, VEGF increased
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FIGURE 7 | Confirmation of functional TRPM8 expression in HCK. The pharmacological changes were carried out at the time points indicated by arrows. Data are
mean ± SEM of 5-20 experiments. (A) Menthol (500µM) induced an irreversible increase in Ca2+ influx (n = 20) whereas non-treated control cells showed a constant
Ca2+ baseline (n = 15). (B,C) Same experiments as shown in (A), but in the presence of BCTC (B), and AMTB (C). Both AMTB and BCTC (both 20µM) clearly
suppressed the menthol-induced Ca2+ increase (n = 5–14). (D) Summary of the experiments with menthol, AMTB, and BCTC. The asterisks (*) designate
significance difference between with and without menthol, a TRPM8 agonist (n = 5–20; p < 0.05 at the minimum; paired tested). The hashtags (#) indicate statistically
significant differences of fluorescence ratios with and without BCTC or AMTB (p < 0.05 at the minimum; unpaired tested).
the f340nm/f380nm ratio from 0.1041 ± 0.001 (200 s) to 0.1892
± 0.012 (600 s) (recovery occurred to 0.1139 ± 0.002 (1,200 s)
(n = 12; p < 0.01; paired tested; Figures 10E,F) whereas CPZ
was again able to suppress the VEGF-induced Ca2+ increase.
Without CPZ, the f340nm/f380nm ratio increased from 0.1043 ±
0.001 (50 s) to 0.1717 ± 0.030 (140 s) (n = 8; p < 0.01; paired
tested) whereas this increase was suppressed in the presence
of 10µM CPZ to 0.0911 ± 0.004 (140 s) (n = 10; p < 0.005;
unpaired tested; Figures 10G,H,I). In addition, VEGF (10 ng/ml)
increased the whole-cell inward currents from −14 ± 6 pA/pF
to −25 ± 8 pA/pF (n = 10; p < 0.001), whereas the outward
currents increased from 80 ± 19 pA/pF to 107 ± 21 pA/pF
(n = 10; p < 0.01) (Figures 11A,C). Consistent with crosstalk
between VEGFR and TRPV1, these current rises were delayed
in some of the experiments (Figure 11A). In contrast, 10µM
CPZ immediately inhibited the rises in the inward currents to
−18 ± 8 pA/pF; n = 7; p < 0.05) and the outward currents
to 79 ± 24 pA/pF (n = 7; p < 0.05; Figures 11A,B,C). On
the other hand, 10 ng/ml VEGF increased outward currents
from 105 ± 21 pA/pF to 159 ± 25 pA/pF (n = 9; p < 0.01)
and inward currents increased from −12 ± 2 pA/pF to −27
± 4 pA/pF (n = 9; p < 0.01; Figures 11D,E,F). AMTB did
not suppress these currents (Figure 11D). This antagonist even
slightly increased the inward currents to −35 ± 6 pA/pF (n
= 9; p < 0.05). To confirm that VEGFR-mediates TRPV1
activation, CPZ preincubation blocked VEGF-induced Ca2+
transients using the aforementioned alternative fluorescence
detection method. Taken together, VEGFR activation by VEGF
solely increases Ca2+ influx through increasing TRPV1-induced
Ca2+ influx and its underlying whole-cell currents.
Thyronamine (3-T1AM) Suppresses
VEGF-Induced Increases in Whole-Cell
Currents
3-T1AM (1µM) increased the f340nm/f380nm ratio from 1.2000
± 0.0005 to 1.2040 ± 0.0009 (350 s) in HCK (n = 6; p <
0.05) (Figure 11H), which was similar to the increase induced
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FIGURE 8 | Additional confirmation of functional TRPM8 expression in HCK. The thermal and pharmacological changes were carried out at the time points indicated
by arrows. Data are mean ± SEM of 5-30 experiments. (A) Temperature lowering from ≈ 23◦C to ≈ 14◦C resulted in an increase [Ca2+]i influx (n = 6). The
corresponding temperature time course is shown above the Ca2+ traces. Untreated cells maintained stable [Ca2+]i levels (control; n = 30). (B) Icilin (60µM) induced
an irreversible increase in Ca2+ influx (n = 13) whereas non-treated control cells showed a constant Ca2+ baseline (n = 30). (C) Same experiment as shown in (B),
but in the presence of BCTC. BCTC (20µM) clearly suppressed the icilin-induced Ca2+ increase (n = 5). (D) Same experiment as shown in (B), but in the presence of
AMTB with the same result as obtained with BCTC (n = 7). (E) Summary of the experiments with icilin, BCTC and AMTB. The asterisks (*) indicate significant
differences between [Ca2+]i levels with icilin and in the presence or absence of BCTC or AMTB (n = 5–13; p < 0.01 at the minimum; paired tested). The hashtag (#)
denotes a statistically significant difference in the fluorescence ratios between icilin with and without BCTC and AMTB, respectively (n = 5–13; p < 0.01 at the
minimum; unpaired tested). (F) Icilin (10µM) induced a partial reversible increase in Ca2+ influx (n = 16). (G) Same experiment as shown in (F), but in the presence of
AMTB. AMTB (10µM) suppressed the icilin-induced Ca2+ increase (n = 16). (H) Summary of the experiments with icilin. The asterisks (*) designate significant
increases in [Ca2+]i with icilin (n = 16; p < 0.005; paired tested). The hashtag (#) denotes a statistically significant difference in fluorescence ratios between icilin with
and without AMTB (n = 16; p < 0.05; non-paired tested).
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FIGURE 9 | Menthol and icilin activated whole-cell currents in HCK. (A) Time course recording showing the current increases induced by icilin (60µM) and declines
after application of 20µM BCTC. (B) Original traces of icilin-induced current responses to voltage ramps. Current densities are shown before application (labeled as
A), during application of 60µM icilin (labeled as B), and after addition of 20µM BCTC (labeled as C). Current densities as function of voltage were derived from the
traces shown in (A). (C) Time course recording showing the current increases induced by menthol (100µM) and declines after application of 20µM AMTB. (D)
Original traces of menthol-induced current responses to voltage ramps. Current densities are shown before application (labeled as A), during application of 100µM
menthol (labeled as B), and after addition of 20µM AMTB (labeled as C). Current densities as function of voltage were derived from the traces shown in (C). (E)
Summary of patch-clamp experiments with icilin and BCTC. The asterisks (*) indicate statistically significant differences between in- and outward whole-cell currents
with and without icilin (n = 16; p < 0.001; paired tested) and significant difference of inward currents between icilin with and without BCTC (n = 4; p < 0.05; unpaired
tested). (F) Summary of patch-clamp experiments with menthol and AMTB. The asterisks (*) indicate statistically significant differences of in- and outward whole-cell
currents with and without menthol (n = 10; p < 0.001; paired tested) and significant difference of inward currents between menthol with and without AMTB (n = 5; p
< 0.05; paired tested).
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FIGURE 10 | VEGF elicits increases in Ca2+ entry through TRPV1 activation in HCK. The pharmacological changes were carried out at the time points indicated by
arrows. Data are mean ± SEM of 4-12 experiments. (A) VEGF (10 ng/ml) induced an irreversible Ca2+ influx (n = 12) whereas non-treated control cells showed a
constant Ca2+ baseline (n = 4). (B,C) Same experiments as shown in (A), but in the presence of CPZ (B) and AMTB (C). Whereas, CPZ (10µM) clearly suppressed
(Continued)
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FIGURE 10 | the VEGF-induced Ca2+ increase (n = 4) AMTB (20µM) failed to suppress the VEGF-induced Ca2+ increase (n = 4). (D) Summary of the experiments
with VEGF, CPZ and AMTB. The asterisks (*) designate significance differences with and without the respective TRPV1 and TRPM8 channel antagonists (CPZ/AMTB)
(n = 4–12; p < 0.05 at the minimum; paired tested). The hashtags (#) indicate statistically significant differences of fluorescence ratios with and without CPZ (n =
4–12; p < 0.01 at the minimum; unpaired tested). (E) VEGF (10 ng/ml) induced a reversible Ca2+ increase (20min) (n = 12). (F) Summary of the long-term recording
with VEGF. The asterisks (*) designate significance differences with and without VEGF (n = 12; p < 0.001). (G) VEGF (10 ng/ml) induced a Ca2+ increase (n = 8)
whereas non-treated control cells showed a constant Ca2+ baseline (n = 10). (H) Same experiments as shown in (G), but in the presence of CPZ. CPZ (10µM)
clearly suppressed the VEGF-induced Ca2+ increase (n = 10). (I) Summary of the experiments with VEGF and CPZ. The asterisks (*) designate significance in [Ca2+]i
with VEGF (n = 8; p < 0.01; paired tested). The hashtag (#) denotes a statistically significant difference of fluorescence ratios with and without CPZ (n = 8–10; p <
0.001; unpaired tested).
by menthol (1.2050 ± 0.0012; n = 6; p < 0.01) (Figures 11G, I).
The increases in the inward whole-cell currents induced by
VEGF (10 ng/ml) shown in Figure 11 are similar to those shown
in Figure 12. Figure 12A shows maximum in- and outward
whole-cell currents under control conditions (marked as A)
and in the presence of 10 ng/ml VEGF (shown in green and
marked as B). After extracellular application of 1µM 3-T1AM,
the currents decreased after a short delay (shown in red and
marked as C). The corresponding current voltage relationships
at the aforementioned points of time (A, B, and C) are shown in
Figure 12B. This experiment was repeated using a step protocol
instead of a voltage ramp protocol (from −60 to +130mV in
10mV steps at a holding potential of 0mV). Figure 12C shows
the corresponding whole-cell currents under control conditions,
which were increased in the presence of VEGF (Figure 12D).
Notably, the inward currents were completely suppressed in
the presence of 3-T1AM since the inward currents are mainly
attributable to increases in Ca2+ influx (Ca2+ free internal
solution) (Figure 12E). The corresponding current voltage
relationships from the recordings shown in Figures 12C,D,E are
summarized in Figure 12F, which clearly demonstrate that the
VEGF-induced current increase could be blocked by 3-T1AM.
Figure 12G summarizes the statistical analysis of all patch-clamp
experiments. Specifically, the inward currents rose from −15 ±
3 pA/pF to −24 ± 4 pA/pF (n = 16; p < 0.0005). Similar to
CPZ, 1µM 3-T1AM suppressed the inward currents (−19 ± 5
pA/pF; n = 16; p < 0.05; Figure 12G). The same pattern was
seen in the outward currents. VEGF increased the mean outward
currents from 98 ± 14 pA/pF to 129 ± 14 pA/pF (n = 16; p <
0.01), which were suppressed to 100 ± 16 pA/pF by 3-T1AM (n
= 16; p< 0.05; Figure 12G). Taken together, 3-T1AM suppressed
VEGF-induced increases in the whole-cell currents.
DISCUSSION
Limitations of Therapeutic Intervention of
Corneal Neovascularization
Corneal neovascularization (CNV) is a severe pathological
condition that may profoundly impair vision. Although its
clinical impact is very well known, novel strategies are still needed
to prevent infiltration of incompletely formed blood vessels. This
maladaptive response to either infection, trauma, toxic agents
or inflammation accounts for a significant number of patients
seen in clinical practice (81). Angiogenesis is also a significant
risk factor for keratoplasty because neovascularization develops
in 41% of the cases undergoing this procedure (82). Furthermore,
medical interventions are only partially successful because
they do not fully reduce neovascularization through topical,
subconjunctival, and intraocular application of bevacizumab
[reviewed (83)]. Alternatively, glucocorticoids are used but they
do not regress preexisting CNV [reviewed (84)]. Furthermore,
chronic usage of steroids to reduce inflammation often has
ocular side effects such as cataracts, glaucoma and superinfection
(85). Another limitation involves their short duration of action.
Rapamycin also has limited effectiveness in inhibiting CNV
induced by a chemical burn through suppressing themammalian
target of rapamycin (mTOR) signaling pathway in a mouse
corneal wound healing model (86, 87). Even though CNV
declined, it was accompanied by increases in proinflammatory
cytokines and decreases in anti-inflammatory cytokines. These
latter effects may instead aggravate infection driven immune-
induced inflammation (88). Such complications account for
continuing efforts to develop alternative strategies for more
effective suppression of neovascularization (89).
Biomarker Validation of HCK Identity
Biomarker expression patterns confirmed the practicality of
using the HCK cell line as an in vitro test model (Figure 1).
Even though, LUM is also expressed by other cell types in
the heart and lung (32, 90), it is coexpressed with KTN,
which is a more selective keratocyte biomarker than LUM
(32) (Figure 1C). Furthermore, CD90, a mesenchymal stem
cell marker, was evident (Figure 2). This expression pattern
documents the heterogeneity of cell types found in stromal
isolates of human corneal tissue (25, 26, 91). Myofibroblasts
were also detected based on a more intense α-SMA staining
pattern than that of KTN (Figure 1B). Furthermore, fibroblast
and myofibroblast coexistence is consistent with numerous
reports showing that keratocyte phenotype maintenance is very
condition dependent. For example, environmental stress or
tissue culture medium content changes can cause keratocytes to
undergo a differentiation program. As a result, this transition can
lead to fibroblasts and ultimately myofibroblast differentiation
(66, 68).
Specificity of TRPV1 Activation
TRPV1 protein expression in stromal keratocytes, HCCS, pHCF
(Figure 3) and HCK (Figures 4A,B), agrees with its presence
in human corneal fibroblasts (13). The CAP-induced Ca2+
transients in corneal epithelial cells closely resemble those
obtained with the HCK cell line (16). The irreversibility of
these transients in some tissues may be related to differences
Frontiers in Endocrinology | www.frontiersin.org 17 November 2018 | Volume 9 | Article 670
Türker et al. VEGFR and TRPV1-TRPM8 Crosstalk
FIGURE 11 | Effect of VEGF, menthol and 3-T1AM on Ca
2+ regulation in HCK. (A) Time course recording showing the current increases induced by 10 ng/ml VEGF
and current density levels after adding CPZ (10µM). There was a delayed increase in the whole-cell currents. (B) Original traces of VEGF-induced current responses
to voltage ramps. Current densities are shown before application (labeled as A), during application of VEGF (labeled as B), and after addition of CPZ (labeled as C).
Current densities as function of voltage were derived from the traces shown in panel A. Notably, VEGF-induced in- and outward currents declined in the presence of
CPZ. (C) Summary of the experiments with VEGF and CPZ. The asterisks (*) indicate statistically significant differences of VEGF-induced increases of in- and outward
currents (n = 10; p < 0.01 at the minimum; paired tested). The hashtag (#) denotes a statistically significant difference in the whole-cell inward currents with and
(Continued)
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FIGURE 11 | without CPZ (n = 7–10; p < 0.05; unpaired tested). (D) Time course recording showing the current increases induced by 10 ng/ml VEGF and current
density levels after adding AMTB (20µM). (E) Original traces of VEGF-induced current responses to voltage ramps. Current densities are shown before application
(labeled as A), during application of VEGF (labeled as B), and after addition of AMTB (labeled as C). Current densities as function of voltage were derived from the
traces shown in (D). (F) Summary of the experiments with VEGF and AMTB. Same statistical analyses as those described in (C) but with AMTB instead of CPZ (n = 9;
*p < 0.01; #p < 0.05). (G) Menthol (500µM) induced a Ca2+ increase (n = 6) whereas non-treated control cells showed a constant Ca2+ baseline (n = 6). (H) Same
experiments as shown in (G), but with 3-T1AM (1µM) (n = 6). (I) Summary of the experiments with menthol and 3-T1AM. The asterisks (*) designate significance in
[Ca2+]i with menthol (n = 6; **p < 0.01) or with 3-T1AM (n = 6; *p = 0.05; both paired tested).
in its tissue specific binding to TRPV1. Functional TRPV1
expression was also confirmed by showing that raising the
bath temperature above 43◦C induced rises in Ca2+ levels
that were partially reversible (92). Differences in reversibility
were also found between pterygial cells and HCjEC. The poor
reversibility in the immortalized HCK cell line corresponds
with what was described in non-malignant pterygial cells and
healthy HCjEC (16). As shown in Figure 3, not all HCK
cells were stainable. This staining inhomogeneity is consistent
with the presence of fibroblasts and myofibroblasts derived
from keratocytes. Notably, TRPV1 and α-SMA are coexpressed,
which is characteristic of myofibroblasts (38). Furthermore, their
coexpression was described in a report showing that TRPV1
upregulation promotes α-SMA expression during myofibroblast
transdifferentiation (93). Such an association may be needed for
TRPV1 to mediate control of actin assembly and disassembly
that occurs during upregulation of this contractile protein. This
type of dependence was described in F11 cells transduced with
retroviral particles obtained from a triple transfection of human
embryonic kidney (HEK)293T cells with TRPV1 plasmids (93).
CAP concentrations (10–20µM) led to Ca2+ transients and
whole-cell current increases (Figures 4D,I, 5A,D). These effects
are in line with those reported in studies using human corneal
endothelial cells (11), corneal epithelial cells (60), retinoblastoma
cells (70), and in neuroendocrine tumor cells (71). The CAP-
induced changes of ≈20 pA/pF in either direction are moderate
(e.g., Figures 5A,B,C) and may be mixed by heterogeneous
responses of different cell types in the HCK cell line. As
previously described, L-carnitine is able to suppress TRPV1
activation (Figures 5A,B,C) and Ca2+ influx (Figures 5D,E,F),
which makes this osmoprotectant relevant for possible use in a
clinical setting (e.g., dry eye) (15, 94–96). Taken together, CAP
has adequate TRPV1 selectivity to be used as a marker of its
expression (24, 46). Even though CPZ only blocks the vanilloid
site on TRPV1, it is the first identified competitive antagonist of
capsaicin, which is a sensory neuronal excitant. Accordingly, it is
universally accepted as a relevant TRPV1 probe (24, 46, 97).
Specificity of TRPM8 Activation
TRPM8 gene and protein expression levels (Figures 6A,B,C,D,E)
in HCK and HCCS cells (Figures 6F,G) are similar to
those described in human corneal (HCEC) and conjunctival
epithelial cells (HCjEC) (42, 43). Even though there is a poor
correspondence between the extensive and rather intense TRPM8
immunostaining and low level of TRPM8 gene expression, this
disparity may be attributable to reported limited selectivity
of the commercially available TRPM8 antibodies (16, 42, 43).
Nevertheless, menthol (100–500µM) induced Ca2+ transients
and increases in whole-cell currents corresponding to those
reported in HCEC and HCjEC (42, 43). These high menthol
concentrations were appropriate because concentrations as
high as 1mM were used for describing functional TRPM8
expression in some other studies (74). Similarly, inhibition by
AMTB of these menthol induced responses confirmed TRPM8
involvement (Figure 7A) (98). Non-specific menthol effects
cannot be excluded because the current rises were not fully
reversible at higher menthol concentrations (> 100µM). At
these concentrations, an irreversible rise in intracellular Ca2+
levels occurred in human corneal endothelial cells (HCEC-12)
and in TRPM8-overexpressing HEK293 cells (99) whereas in
HCEC-12 a reversible effect was detectable (41). BCTC and
AMTB are well-established TRPM8 antagonists, but AMTB
is only TRPM8 selective whereas BCTC is also a TRPV1
antagonist (21, 24, 100). Nevertheless, both BCTC and AMTB
had similar inhibitory effects on TRPM8 activation induced by
either menthol or icilin (Figures 7–9) (98, 101). Specifically,
icilin, which is a mixed TRPM8/ TRPA1 agonist (79) also
irreversibly increased intracellular Ca2+ in HCEC and HCjEC
(42–44) whereas these increases were also inhibited by AMTB
confirming TRPM8 involvement in HCK (Figures 8D,G) (42–
44). As icilin is both a super-cooling TRPM8 agonist, and a weak
TRPA1 agonist (44, 102), its effectsmay include TRPA1 activation
at either a high icilin/menthol concentration or cooling to≈14◦C
(Figure 8A) (79). Nevertheless, the menthol/AMTB effects are
very likely solely attributable to TRPM8 activation because icilin
had effects that can only be accounted for by TRPM8 activation
inmutant mice (98). In the current study, icilin induced increases
in the intracellular Ca2+ levels and the whole-cell currents which
were inhibited by both BCTC and AMTB (Figure 9). These
inhibitory effects were similar to those occurring in HCEC
(42). 3-T1AM was used as probe of thermo-sensitive TRPM8
involvement in mediating temperature lowering in rodents (20).
Even though the responses induced by this thyroxine metabolite
also included an interaction of TRPM8 with a GPCR in some
other cell types, we did not deal with this possibility (4).
VEGF Interacts With TRPV1
The Ca2+transients and underlying ionic currents induced by
VEGF are similar to those in microvascular endothelial cells and
podocytes in which these responses were instead mediated by
crosstalk with TRP canonical 6 (TRPC6) rather than TRPV1
(103, 104). In HCK, TRPV1 is solely involved because CPZ
completely blocked these effects whereas AMTB had no effect
(Figure 10). Unlike CPZ, AMTB instead slightly enhanced
VEGF-induced whole-cell current, which supports the notion
of TRPM8 suppressing crosstalk between TRPV1 and VEGFR
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FIGURE 12 | 3-T1AM suppresses VEGF-induced increases in whole-cell currents in HCK. (A) Time course recording showing the current increases induced by
10 ng/ml VEGF and current density levels after adding 3-T1AM (1µM). There was a delayed increase and decrease of whole-cell currents, respectively. (B) Original
traces of VEGF-induced current responses to voltage ramps. Current densities are shown before application (black labeled as A), during application of VEGF (green
labeled as B), and after addition of 3T1AM (red labeled as C). Current densities as function of voltage were derived from the traces shown in (A). Notably, there was a
decrease of VEGF-induced in- and outward currents in the presence of 3-T1AM. (C) Whole-cell currents under control conditions induced by depolarization from −60
to 130mV in 10mV steps (400ms). (D) Increased whole-cell currents (green traces) in the presence of 10 ng/ml VEGF. (E) Decreased whole-cell currents (red traces)
in the additional presence of 1µM 3-T1AM. (F) Effect of VEGF and 3-T1AM summarized in a current/voltage plot [I-V plot, data obtained from (C–E)]. The black trace
(filled circles) was obtained under control conditions. The green trace was obtained in the presence of 10 ng/ml VEGF and the lower red trace in the additional
presence of 3-T1AM. An inhibitory effect could be observed. (G) Summary of the experiments with VEGF and 3-T1AM. The asterisks (*) indicate statistically significant
differences of in- and outward currents with and without 3-T1AM (n = 16; p < 0.05 at the minimum; paired tested).
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(Figures 11D,E,F). The time delays seen in some cases in VEGF-
induced rises in whole-cell currents and Ca2+ transients are
probably due to drug diffusion delays (Figure 11A).
3-T1AM Involvement in VEGF Signaling
In this study, 3-T1AM blunting of the crosstalk between
VEGFR and TRPV1 is similar to its inhibitory effect on TRPV1
activation by CAP in HCEC and HCjEC (42, 43). Other
evidence supportive of crosstalk among these receptor triad
members stems from the fact that AMTB increased inward
currents induced by VEGF (Figures 11D,E,F) whereas 3-T1AM
blunted VEGF-induced increases in whole-cell currents using a
voltage ramp protocol (Figures 12A,B) or a voltage step protocol
(Figures 12C,F). The current voltage relationships are consistent
with TRP behavior described in previous studies of corneal
cells (e.g., reversal potential, outwardly rectifying currents) (e.g.,
(13, 60)). Interestingly, 3-T1AM had a delayed response which
may be possibly attributable to a diffusion delay to an intracellular
binding site. Another possibility requiring further study is that 3-
T1AM instead indirectly targets TRPV1 via directly promoting
the inhibitory effect of the (soluble) VEGF receptor 1 on VEGFR,
which is also expressed in the cornea (55, 105). Such control
by TRPM8 can be even more complex and may also involve
interactions with adrenergic receptors (106).
Potential Therapeutic Targets
This study provides additional supportive evidence that TRPV1
is a potential drug target for improving treatment of VEGF-
induced neovascularization. Such an effect may be obtainable by
suppressing VEGFR crosstalk with TRPV1 through increasing
TRPM8 activity with an agonist such as thyronamine (3-
T1AM). This strategy may provide a selective approach to inhibit
TRPV1 upregulation and activation, which in turn suppresses
angiogenesis, fibrosis as well as inflammatory processes in
different pathophysiological conditions such as dry eye disease
(DED), pterygium, and conjunctivitis sicca or red eyes (16, 94,
107). 3-T1AM may also be beneficial in the treatment of DED
(42, 43, 49) since TRPM8 activation triggers increases in tear fluid
production by the lacrimal gland via activation of the Central
Nervous System (CNS) (40). In this context, borneol is another
TRPM8 agonist, which provided symptomatic relief to DED
patients when it was applied as eye drops (108–110).
CONCLUSIONS
VEGF-induces Ca2+ transients by transactivating TRPV1,
whereas TRPM8 activation suppresses this response by blocking
TRPV1 activation. Accordingly, VEGF-induced corneal
neovascularization may be inhibited by novel TRPM8 agonists
such as 3-T1AM.
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